20:15 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Sunovion's PD therapy NDA gets PDUFA date

Sunovion Pharmaceuticals Inc. said FDA accepted an NDA for apomorphine sublingual film (APL-130277) to treat "off" episodes in Parkinson's disease (PD). The PDUFA date is Jan. 29, 2019. Sunovion, a unit of Sumitomo Dainippon Pharma Co....
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
19:53 , Jul 28, 2017 |  BC Week In Review  |  Company News

Mitsubishi acquiring NeuroDerm

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) will acquire neurology company NeuroDerm Ltd. (NASDAQ:NDRM) for $1.1 billion at a price of $39 per share. The price is 17% premium over the share’s July 21 close of $33.20. The...
19:40 , Jul 24, 2017 |  BC Extra  |  Company News

Mitsubishi Tanabe acquiring NeuroDerm

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) is acquiring neurology company NeuroDerm Ltd. (NASDAQ:NDRM) for $39 per share, or about $1.1 billion. The price is a 17% premium on NeuroDerm's July 21 close of $33.20. The deal gives...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Cynapsus, Sumitomo Dainippon deal

Sumitomo’s Sunovion Pharmaceuticals Inc. unit will acquire Cynapsus for $40.50 per share in a cash deal the companies say values Cynapsus at about $624 million. The price is a 121% premium to Cynapsus’ close of...
07:00 , Aug 31, 2016 |  BC Extra  |  Top Story

Sunovion to acquire Cynapsus for $624M

The Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) announced after market close Wednesday that it will acquire neurology company Cynapsus Therapeutics Inc. (TSX:CTH; NASDAQ:CYNA) for about $624 million in cash. Sunovion...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

ND0701: Clinical trial started

NeuroDerm began a crossover bioequivalence trial to compare subcutaneous ND0701 apomorphine base vs. marketed subcutaneous apomorphine HCl for 12 hours in about 18 healthy volunteers. NeuroDerm Ltd. (NASDAQ:NDRM), Ness Ziona, Israel   Product: ND0701   Business:...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

APL-130277: Preliminary Phase III data

Preliminary data from 92 evaluable PD patients in the open-label, dose-escalation portion of the U.S. Phase III CTH-300 trial showed that sublingual APL-130227 improved mean MDS-UPDRS Part III score from baseline to 30 and 90...
07:00 , Jul 19, 2016 |  BC Extra  |  Clinical News

Cynapsus reports early Phase III data for PD candidate

Cynapsus Therapeutics Inc. (TSX:CTH; NASDAQ:CYNA) reported data from the open-label, dose-escalation portion of the Phase III CTH-300 study evaluating APL-130277 to treat "off" episodes in patients with Parkinson's disease (PD). In 92 evaluable PD patients,...
07:00 , Apr 18, 2016 |  BC Week In Review  |  Company News

MonoSol Rx, Cynapsus deal

MonoSol granted Cynapsus exclusive, worldwide rights to IP covering oral apomorphine-containing films to treat “off” episodes of Parkinson’s disease (PD). Cynapsus said the deal strengthens the IP covering its APL-130277. The sublingual thin film...